Current state and future directions of EGFR-directed therapy in head and neck cancer
P Tathineni, N Joshi, MJ Jelinek - Current Treatment Options in Oncology, 2023 - Springer
Opinion Statement Epidermal growth factor receptor (EGFR) is commonly overexpressed in
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
[HTML][HTML] Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …
originated from oral cavity. Though the prognostic and predictive value of targeting …
Oral mucositis: Current knowledge and future directions
SS Shetty, M Maruthi, V Dhara, JAA de Arruda… - Disease-a-Month, 2022 - Elsevier
Oral mucositis secondary to head and neck chemoradiation displays a complex molecular
pathogenesis involving epithelial and microvascular injury, release of pro-inflammatory …
pathogenesis involving epithelial and microvascular injury, release of pro-inflammatory …
[HTML][HTML] Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma
C Palumbo, M Benvenuto, C Focaccetti… - Frontiers in …, 2023 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type,
has often an aggressive course and is poorly responsive to current therapeutic approaches …
has often an aggressive course and is poorly responsive to current therapeutic approaches …
[HTML][HTML] T cell effects and mechanisms in immunotherapy of head and neck tumors
Y Xiang, M Gong, Y Deng, H Wang, D Ye - Cell Communication and …, 2023 - Springer
Head and neck tumors (HNCs) are a common tumor in otorhinolaryngology head and neck
surgery, accounting for 5% of all malignant tumors in the body and are the sixth most …
surgery, accounting for 5% of all malignant tumors in the body and are the sixth most …
[HTML][HTML] Immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
RW Hsieh, S Borson, A Tsagianni… - Frontiers in oncology, 2021 - frontiersin.org
Head and neck cancer is the 6th most common cancer worldwide with the most common
histology being squamous cell carcinoma (HNSCC). While the majority of patients present at …
histology being squamous cell carcinoma (HNSCC). While the majority of patients present at …
[HTML][HTML] Advantages of the combinatorial molecular targeted therapy of head and neck cancer—A step before anakoinosis-based personalized treatment
R Kleszcz - Cancers, 2023 - mdpi.com
Simple Summary Head and Neck Squamous Cell Carcinoma (HNSCC) is a major threat to
public health around the world. Its occurrence is linked to genetic events and environmental …
public health around the world. Its occurrence is linked to genetic events and environmental …
Pembrolizumab in the first-line treatment of advanced head and neck cancer
LG de Sousa, R Ferrarotto - Expert review of anticancer therapy, 2021 - Taylor & Francis
Introduction Recurrent or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD …
(HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD …
Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma
JE Mann, JD Smith, A Kulkarni, SK Foltin, EB Scheftz… - Oral Oncology, 2023 - Elsevier
Head and neck squamous cell carcinomas (HNSCC) are associated with significant
treatment-related morbidity and poor disease-free and disease-specific survival, especially …
treatment-related morbidity and poor disease-free and disease-specific survival, especially …
BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling to durably suppress tumor growth
SR Boreddy, R Nair, PK Pandey, A Kuriakose… - Cancer Research, 2023 - AACR
The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, and
cross-talk between them contributes to cancer progression and drug resistance. Therapies …
cross-talk between them contributes to cancer progression and drug resistance. Therapies …